Bulletin
Investor Alert

Alkermes PLC

NAS: ALKS

GO

Set Alerts

Market Index

Overview Profile Charts Financials Historical Quotes Analyst Estimates Options SEC Filings Insiders
/marketstate/country/us
Alkermes PLC

After Hours

 --Quotes are delayed by 20 min

Mar 27, 2023, 4:48 p.m.

ALKS
/zigman2/quotes/205084517/composite

$

27.01

Change

0.00 0.00%

Volume

Volume 120,818

Quotes are delayed by 20 min

/zigman2/quotes/205084517/composite

Previous close

$ 26.49

$ 27.01

Change

+0.52 +1.96%

Day low

Day high

$26.45

$27.20

Open

52 week low

52 week high

$21.75

$32.79

Open

Company Description

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I diso...

Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. Its proprietary products include ARISTADA, ARISTADA INITIO, LYBALVI, and VIVITROL. The company was founded in 1987 and is headquartered in Dublin, Ireland.

Valuation

Price to Sales Ratio

3.84

Price to Book Ratio

4.12

Price to Cash Flow Ratio

78.74

Enterprise Value to EBITDA

-62.47

Enterprise Value to Sales

3.62

Total Debt to Enterprise Value

0.10

Efficiency

Revenue/Employee

487,629.00

Income Per Employee

-69,415.00

Receivables Turnover

3.57

Total Asset Turnover

0.56

Liquidity

Current Ratio

2.27

Quick Ratio

1.91

Cash Ratio

1.22

Profitability

Gross Margin

76.03

Operating Margin

-12.80

Pretax Margin

-15.05

Net Margin

-14.24

Return on Assets

-7.94

Return on Equity

-14.68

Return on Total Capital

-9.58

Return on Invested Capital

-10.79

Capital Structure

Total Debt to Total Equity

38.21

Total Debt to Total Capital

27.65

Total Debt to Total Assets

20.31

Long-Term Debt to Equity

36.42

Long-Term Debt to Total Capital

26.35

Officers and Executives

Name Age Officer Since Title
Mr. Richard F. Pops 58 1991 Chief Executive Officer & Director
Mr. Blair C. Jackson 48 1999 Senior Vice President-Corporate Planning
Mr. Iain Michael Brown 50 2003 Chief Accounting Officer & Senior VP-Finance
Ms. Sondra Smyrnios - 2019 Senior Vice President-Clinical Operations
Dr. Kanchan Relwani - 2017 Senior Vice President-Medical Affairs

Insider Actions

– Purchase – Sale 1 – Number of Transactions
Date Name Shares Transaction Value
02/22/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		2,462   Derivative/Non-derivative trans. at $27.77 per share. 68,369
02/22/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		3,224   Derivative/Non-derivative trans. at $27.77 per share. 89,530
02/22/2023 Blair C. Jackson
EVP, Chief Operating Officer 		3,088   Derivative/Non-derivative trans. at $27.77 per share. 85,753
02/22/2023 Iain Michael Brown
SVP, Chief Financial Officer 		2,049   Derivative/Non-derivative trans. at $27.77 per share. 56,900
02/22/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		5,345   Derivative/Non-derivative trans. at $27.77 per share. 148,430
02/22/2023 C. Todd Nichols
SVP, Chief Commercial Officer 		2,704   Derivative/Non-derivative trans. at $27.77 per share. 75,090
02/22/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		5,544   Derivative/Non-derivative trans. at $0 per share. 0
02/22/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		7,286   Derivative/Non-derivative trans. at $0 per share. 0
02/22/2023 Blair C. Jackson
EVP, Chief Operating Officer 		9,504   Derivative/Non-derivative trans. at $0 per share. 0
02/22/2023 Iain Michael Brown
SVP, Chief Financial Officer 		6,969   Derivative/Non-derivative trans. at $0 per share. 0
02/22/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		12,038   Derivative/Non-derivative trans. at $0 per share. 0
02/22/2023 C. Todd Nichols
SVP, Chief Commercial Officer 		6,969   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2023 Richard F. Pops
Director and CEO, Alkermes plc; Director 		14,386   Derivative/Non-derivative trans. at $27.77 per share. 399,499
02/21/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		2,587   Derivative/Non-derivative trans. at $27.77 per share. 71,840
02/21/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		2,022   Derivative/Non-derivative trans. at $27.77 per share. 56,150
02/21/2023 Blair C. Jackson
EVP, Chief Operating Officer 		1,412   Derivative/Non-derivative trans. at $27.77 per share. 39,211
02/21/2023 Iain Michael Brown
SVP, Chief Financial Officer 		1,412   Derivative/Non-derivative trans. at $27.77 per share. 39,211
02/21/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		3,053   Derivative/Non-derivative trans. at $27.77 per share. 84,781
02/21/2023 Richard F. Pops
Director and CEO, Alkermes plc; Director 		32,400   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		5,825   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		6,875   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2023 Blair C. Jackson
EVP, Chief Operating Officer 		4,800   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2023 Iain Michael Brown
SVP, Chief Financial Officer 		4,800   Derivative/Non-derivative trans. at $0 per share. 0
02/21/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		6,875   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2023 Richard F. Pops
Director and CEO, Alkermes plc; Director 		53,145   Derivative/Non-derivative trans. at $28.07 per share. 1,491,780
02/20/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		5,226   Derivative/Non-derivative trans. at $28.07 per share. 146,693
02/20/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		2,378   Derivative/Non-derivative trans. at $28.07 per share. 66,750
02/20/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		4,548   Derivative/Non-derivative trans. at $28.07 per share. 127,662
02/20/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		2,069   Derivative/Non-derivative trans. at $28.07 per share. 58,076
02/20/2023 Blair C. Jackson
EVP, Chief Operating Officer 		2,966   Derivative/Non-derivative trans. at $28.07 per share. 83,255
02/20/2023 Blair C. Jackson
EVP, Chief Operating Officer 		1,350   Derivative/Non-derivative trans. at $28.07 per share. 37,894
02/20/2023 Iain Michael Brown
SVP, Chief Financial Officer 		2,966   Derivative/Non-derivative trans. at $28.07 per share. 83,255
02/20/2023 Iain Michael Brown
SVP, Chief Financial Officer 		1,350   Derivative/Non-derivative trans. at $28.07 per share. 37,894
02/20/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		6,526   Derivative/Non-derivative trans. at $28.07 per share. 183,184
02/20/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		3,780   Derivative/Non-derivative trans. at $28.07 per share. 106,104
02/20/2023 C. Todd Nichols
SVP, Chief Commercial Officer 		6,753   Derivative/Non-derivative trans. at $28.07 per share. 189,556
02/20/2023 C. Todd Nichols
SVP, Chief Commercial Officer 		1,125   Derivative/Non-derivative trans. at $28.07 per share. 31,578
02/20/2023 Richard F. Pops
Director and CEO, Alkermes plc; Director 		119,713   Award at $0 per share. 0
02/20/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		11,770   Award at $0 per share. 0
02/20/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		15,468   Award at $0 per share. 0
02/20/2023 Blair C. Jackson
EVP, Chief Operating Officer 		10,086   Award at $0 per share. 0
02/20/2023 Iain Michael Brown
SVP, Chief Financial Officer 		10,086   Award at $0 per share. 0
02/20/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		22,195   Award at $0 per share. 0
02/20/2023 C. Todd Nichols
SVP, Chief Commercial Officer 		22,969   Award at $0 per share. 0
02/20/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		5,354   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		7,036   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2023 Blair C. Jackson
EVP, Chief Operating Officer 		4,589   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2023 Iain Michael Brown
SVP, Chief Financial Officer 		4,589   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		10,095   Derivative/Non-derivative trans. at $0 per share. 0
02/20/2023 C. Todd Nichols
SVP, Chief Commercial Officer 		3,824   Derivative/Non-derivative trans. at $0 per share. 0
02/18/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		2,065   Derivative/Non-derivative trans. at $28.07 per share. 57,964
02/18/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		1,945   Derivative/Non-derivative trans. at $28.07 per share. 54,596
02/18/2023 Blair C. Jackson
EVP, Chief Operating Officer 		2,683   Derivative/Non-derivative trans. at $28.07 per share. 75,311
02/18/2023 Iain Michael Brown
SVP, Chief Financial Officer 		1,965   Derivative/Non-derivative trans. at $28.07 per share. 55,157
02/18/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		2,656   Derivative/Non-derivative trans. at $28.07 per share. 74,553
02/18/2023 C. Todd Nichols
SVP, Chief Commercial Officer 		1,961   Derivative/Non-derivative trans. at $28.07 per share. 55,045
02/18/2023 Michael J. Landine
SVP, Corp Dev., Alkermes, Inc. 		4,361   Derivative/Non-derivative trans. at $0 per share. 0
02/18/2023 David Jose Gaffin
EVP, CLO, Alkermes, Inc. 		6,230   Derivative/Non-derivative trans. at $0 per share. 0
02/18/2023 Blair C. Jackson
EVP, Chief Operating Officer 		8,722   Derivative/Non-derivative trans. at $0 per share. 0
02/18/2023 Iain Michael Brown
SVP, Chief Financial Officer 		6,230   Derivative/Non-derivative trans. at $0 per share. 0
02/18/2023 Craig C. Hopkinson
EVP R&D, Chief Medical Officer 		8,722   Derivative/Non-derivative trans. at $0 per share. 0
02/18/2023 C. Todd Nichols
SVP, Chief Commercial Officer 		6,230   Derivative/Non-derivative trans. at $0 per share. 0
02/10/2023 David Antonio Daglio
Director 		4,445   Derivative/Non-derivative trans. at $0 per share. 0
02/10/2023 Brian Patrick McKeon
Director 		4,445   Derivative/Non-derivative trans. at $0 per share. 0
12/08/2022 Cato T. Laurencin
Director 		378   Derivative/Non-derivative trans. at $25.48 per share. 9,631
12/08/2022 Cato T. Laurencin
Director 		385   Derivative/Non-derivative trans. at $25.48 per share. 9,809
12/08/2022 Cato T. Laurencin
Director 		4,082   Derivative/Non-derivative trans. at $0 per share. 0
12/08/2022 Cato T. Laurencin
Director 		4,160   Derivative/Non-derivative trans. at $0 per share. 0
11/14/2022 David Antonio Daglio
Director 		35,000   Acquisition at $23.31 per share. 815,850
06/21/2022 C. Todd Nichols
SVP, Chief Commercial Officer 		7,474   Disposition at $28.26 per share. 211,215
06/14/2022 David Antonio Daglio
Director 		795   Derivative/Non-derivative trans. at $27.19 per share. 21,616
06/14/2022 Shane M. Cooke
Director 		3,945   Derivative/Non-derivative trans. at $27.19 per share. 107,264
06/14/2022 Nancy J. Wysenski
Director 		695   Derivative/Non-derivative trans. at $27.19 per share. 18,897
06/14/2022 Brian Patrick McKeon
Director 		795   Derivative/Non-derivative trans. at $27.19 per share. 21,616
06/14/2022 Nancy L. Snyderman
Director 		695   Derivative/Non-derivative trans. at $27.19 per share. 18,897
06/14/2022 Frank Anders Wilson
Director 		695   Derivative/Non-derivative trans. at $27.19 per share. 18,897
06/14/2022 Richard B. Gaynor
Director 		695   Derivative/Non-derivative trans. at $27.19 per share. 18,897
06/14/2022 Emily Peterson Alva
Director 		905   Derivative/Non-derivative trans. at $27.19 per share. 24,606
06/14/2022 David Antonio Daglio
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Shane M. Cooke
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 David Westbrook Anstice
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Wendy L. Dixon
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Nancy J. Wysenski
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Brian Patrick McKeon
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Nancy L. Snyderman
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Frank Anders Wilson
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Richard B. Gaynor
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/14/2022 Emily Peterson Alva
Director 		7,585   Derivative/Non-derivative trans. at $0 per share. 0
06/09/2022 Emily Peterson Alva
Director 		304   Derivative/Non-derivative trans. at $28.13 per share. 8,551
06/09/2022 Emily Peterson Alva
Director 		43   Derivative/Non-derivative trans. at $28.13 per share. 1,209
06/09/2022 Emily Peterson Alva
Director 		3,796   Derivative/Non-derivative trans. at $0 per share. 0
06/09/2022 Emily Peterson Alva
Director 		532   Derivative/Non-derivative trans. at $0 per share. 0
/news/latest/company/us/alks

MarketWatch News on ALKS

  1. Alkermes, Allakos See Activist Action

    9:30 p.m. Oct. 14, 2022

    - Barron's Online

  2. Alkermes upgraded to neutral from underperform at BofA Securities

    9:48 a.m. Oct. 14, 2022

    - Tomi Kilgore

  3. How to Avoid the Biotech Bear Market: Get Some Products Approved

    9:33 p.m. May 13, 2022

    - Barron's Online

  5. Nektar Shares Halve on Cancer Trial Failure

    6:14 p.m. March 14, 2022

    - Barron's Online

  6. Alkermes downgraded to underperform from neutral at BofA Securities

    9:41 a.m. Sept. 2, 2021

    - Tomi Kilgore

  7. Alkermes stock halted for news pending

    7:00 a.m. June 1, 2021

    - Tomi Kilgore

  8. Biotech Is Down. How It Could Come Back.

    9:41 a.m. May 17, 2021

    - Barron's Online

  9. The Case for AbbVie as a Top Biopharma Stock in 2021

    9:45 a.m. Jan. 7, 2021

    - Barron's Online

  10. Alkermes upgraded to buy from neutral at Mizuho

    6:35 a.m. Oct. 15, 2020

    - Tomi Kilgore

  11. Alkermes stock price target raised to $24 from $19 at Mizuho

    6:04 a.m. Oct. 15, 2020

    - Tomi Kilgore

  13. Alkermes downgraded to neutral from buy at BofA Securities

    11:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  14. Alkermes stock price target cut to $20 from $31 at BofA Securities

    11:40 a.m. Feb. 14, 2020

    - Tomi Kilgore

  15. Alkermes downgraded to neutral from overweight at J.P. Morgan

    8:51 a.m. Feb. 14, 2020

    - Tomi Kilgore

  16. Alkermes stock price target cut to $21 from $25 at J.P. Morgan

    8:52 a.m. Feb. 14, 2020

    - Tomi Kilgore

  17. FDA told Alkermes to stop publishing Vivitrol ad

    1:12 p.m. Dec. 11, 2019

    - Jaimy Lee

  18. Alkermes to acquire Rodin Therapeutics for up to $950 million

    8:30 a.m. Nov. 18, 2019

    - Ciara Linnane

  19. Biogen shares fall 3%

    4:08 p.m. Nov. 14, 2019

    - Jaimy Lee

  21. Loading more headlines...
/news/nonmarketwatch/company/us/alks

Other News on ALKS

  1. 10-K: ALKERMES PLC.

    5:53 p.m. Feb. 16, 2023

    - Edgar Online - (EDG = 10Q, 10K)

  2. Can Drugs Treat Addiction? Prisons Offer an Answer

    3:34 a.m. Dec. 10, 2022

    - The Wall Street Journal Interactive Edition

  4. How Alkermes (ALKS) Stock Stands Out in a Strong Industry

    9:40 a.m. Nov. 23, 2022

    - Zacks.com

  5. Top 5 3rd Quarter Trades of Meditor Group Ltd

    7:00 p.m. Nov. 7, 2022

    - GuruFocus.com

  7. Alkermes plc 2022 Q3 - Results - Earnings Call Presentation

    1:43 p.m. Nov. 2, 2022

    - Seeking Alpha

  8. Alkermes plc (ALKS) Q3 2022 Earnings Call Transcript

    1:41 p.m. Nov. 2, 2022

    - Seeking Alpha

  9. Alkermes (ALKS) Q3 Earnings Meet Estimates, Revenues Miss

    11:43 a.m. Nov. 2, 2022

    - Zacks.com

  11. 10-Q: ALKERMES PLC.

    9:22 a.m. Nov. 2, 2022

    - Edgar Online - (EDG = 10Q, 10K)

  12. Alkermes (ALKS) Q3 Earnings Match Estimates

    8:35 a.m. Nov. 2, 2022

    - Zacks.com

  14. Notable earnings before Wednesday's open

    10:24 a.m. Nov. 1, 2022

    - Seeking Alpha

  17. EMERALD ADVISERS, LLC Buys 1, Sells 4 in 3rd Quarter

    5:00 p.m. Oct. 25, 2022

    - GuruFocus.com

  18. Acorda wins $16.5M in Ampyra arbitration case with Alkermes

    7:53 a.m. Oct. 17, 2022

    - Seeking Alpha

  21. Loading more headlines...

At a Glance

Alkermes Plc

Connaught House

1 Burlington Road

Dublin, Dublin 4

Phone

353 17728000

Industry

Biotechnology

Sector

Health Care/Life Sciences

Fiscal Year-end

12/2023

View SEC Filings

Revenue

$1.11B

Net Income

$-158.27M

Employees

2,280

Annual Report for ALKS

/news/pressrelease/company/us/alks

Press Releases on ALKS

  2. Alkermes to Participate in the Stifel 2023 CNS Days

    4:00 p.m. March 15, 2023

    - PR Newswire - PRF

  9. Alkermes to Participate in the Stifel Healthcare Conference

    5:00 p.m. Nov. 8, 2022

    - PR Newswire - PRF

  10. Alkermes plc Reports Third Quarter 2022 Financial Results

    7:02 a.m. Nov. 2, 2022

    - PR Newswire - PRF

  11. Alkermes plc Announces Intent to Separate Oncology Business

    7:00 a.m. Nov. 2, 2022

    - PR Newswire - PRF

  13. Alkermes to Report Third Quarter Financial Results on Nov. 2, 2022

    4:01 p.m. Oct. 26, 2022

    - PR Newswire - PRF

  17. Alkermes plc Reports Second Quarter 2022 Financial Results

    7:00 a.m. July 27, 2022

    - PR Newswire - PRF

  18. Alkermes to Report Second Quarter Financial Results on July 27, 2022

    4:00 p.m. July 20, 2022

    - PR Newswire - PRF

  20. Sarissa Capital Comments on Alkermes Annual Meeting

    7:04 a.m. July 6, 2022

    - BusinessWire - BZX

  21. Loading more headlines...
Link to MarketWatch's Slice.